A5055837353- Pancreatic and Hepatic Oncology Research
- Cancer Genomics and Diagnostics
- Neuroblastoma Research and Treatments
- Renal cell carcinoma treatment
- Organ Transplantation Techniques and Outcomes
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Genetic factors in colorectal cancer
- Hepatocellular Carcinoma Treatment and Prognosis
- Pancreatitis Pathology and Treatment
- Neuroendocrine Tumor Research Advances
- Cancer Research and Treatments
- Liver Disease and Transplantation
- Organ Donation and Transplantation
- Epigenetics and DNA Methylation
- Gastric Cancer Management and Outcomes
- Glioma Diagnosis and Treatment
- Virus-based gene therapy research
- Liver Disease Diagnosis and Treatment
- Ferroptosis and cancer prognosis
- Transplantation: Methods and Outcomes
- Cancer, Hypoxia, and Metabolism
- Radiomics and Machine Learning in Medical Imaging
- Cytokine Signaling Pathways and Interactions
- Lung Cancer Treatments and Mutations
- Renal Transplantation Outcomes and Treatments
Inserm
2016-2025
Université Paris-Sud
2017-2025
Université Paris-Saclay
2018-2025
Hôpital Paul-Brousse
2017-2025
Assistance Publique – Hôpitaux de Paris
2014-2025
Physiopathogénèse et Traitement des Maladies du Foie
2024
Université Paris Cité
2015-2023
Centre de Recherche des Cordeliers
2019-2023
Sorbonne Université
2014-2023
Centre National de la Recherche Scientifique
2016-2023
In Brief Objective: To evaluate the prevalence of sarcopenia among European patients with resectable hepatocellular carcinoma (HCC) and to assess its prognostic impact on overall disease-free survival. Background: Identification preoperative factors in liver surgery for HCC is required better select improve Recent studies have shown that discrimination low skeletal muscle mass (sarcopenic patients) using computed tomography was associated morbidity mortality after colorectal surgery....
Abstract Purpose: Despite recent therapeutic advances, prognosis of patients with pancreatic adenocarcinoma remains poor. Analyses from tumor tissues present limitations; identification informative marker blood might be a promising alternative. The aim this study was to assess the feasibility and prognostic value circulating DNA (ctDNA) in adenocarcinoma. Experimental Design: From 2011 2015, samples were prospectively collected all consecutive treated our center. Identification ctDNA done...
The intratumoral microenvironment, or stroma, is of major importance in the pathobiology pancreatic ductal adenocarcinoma (PDA), and specific conditions stroma may promote increased cancer aggressiveness. We hypothesized that this heterogeneous evolving compartment drastically influences tumor cell abilities, which turn PDA aggressiveness through crosstalk mediated by extracellular vesicles (EVs). Here, we have analyzed proteomic stromal signature identified a contribution annexin A6/LDL...
<h3>Importance</h3> The benefit of adjuvant chemotherapy after resection pancreatic cancer following neoadjuvant combination treatment with folinic acid, fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX) is unclear. <h3>Objective</h3> To assess the association overall survival (OS) in patients FOLFIRINOX treatment. <h3>Design, Setting, Participants</h3> This international, multicenter, retrospective cohort study was conducted from January 1, 2012, to December 31, 2018. An existing...
Pancreatic ductal adenocarcinoma (PDAC) is characterized by extensive stroma and pathogenic modifications to the peripheral nervous system that elevate metastatic capacity. In this study, we show IL6-related stem cell-promoting factor LIF supports PDAC-associated neural remodeling (PANR). was overexpressed in tumor tissue compared with healthy pancreas, but its receptors LIFR gp130 were expressed only intratumoral nerves. Cancer cells stromal PDAC tissues both LIF, could secrete it....
Importance The effect of adjuvant chemotherapy following resection pancreatic adenocarcinoma after preoperative (m)FOLFIRINOX (combination leucovorin calcium [folinic acid], fluorouracil, irinotecan hydrochloride, and oxaliplatin in full or modified dosing) on overall survival (OS) is unclear because current studies do not account for the number cycles regimen. Objective To investigate association with OS, taking into Design, Setting, Participants This retrospective cohort study included...
Detecting single-nucleotide variations and insertions/deletions in circulating tumor DNA is challenging because of their low allele frequency. The clinical use to characterize genetic alterations requires new methods based on next-generation sequencing.We developed a method quantification error rate each base position [position (PER)]. To identify mutations, binomial test was used compare the minor-allele frequency measured PER at position. This process validated control samples 373 plasma...
In metastatic colorectal cancer (mCRC), circulating tumor DNA (ctDNA) monitoring can be used to genotype tumors and track clonal evolution. We investigated the clearance of RAS mutated clones under chemotherapy pressure by ctDNA analysis in patients with a mCRC. Patients included prospective PLACOL study were monitored for ctDNA. Analyses based on optimized targeted next-generation sequencing and/or droplet-based digital polymerase chain reaction (ddPCR). For plasma samples without...
To validate the prognostic value of PAncreatic NeoAdjuvant MAssachusetts (PANAMA)-score and to determine its predictive ability for survival benefit derived from adjuvant treatment in patients after resection pancreatic ductal adenocarcinoma (PDAC) following neoadjuvant FOLFIRINOX. The PANAMA-score was developed guide prognostication therapy PDAC. As this score focuses on risk residual disease resection, it might also be able select who therapy. This retrospective international multicenter...
<title>Abstract</title> Circulating tumor DNA (ctDNA) is a promising marker with strong prognostic value in metastatic pancreatic ductal adenocarcinoma (mPDAC). However, ctDNA not detected about third of patients mPDAC. The objective this study was to assess the correlation between and volume (TV). In monocentric cohort mPDAC naïve for chemotherapy, quantity at baseline assessed by droplet-based digital PCR targeting two methylated markers (HOXD8 POU4F1). TV measured 3D, primary lesion...